RE: Ciz on Sunday Roast, tipped by Charles Archer26 Nov 2023 20:07
Re Sunday Roast podcast - always have mixed views about this…good to get publicity but also struggle a little re the limited depth of what is explained to listeners…to be expected given range of companies covered.
Thought it would be worth putting some quick notes down in case any new investors take a look in…just off the top of my head, so anyone else feel free to add anything I’ve missed :-)
- Developed out of a research project from York Uni, still operate research from there, 20 years of research under Professor Dawn Coverley leading to current position.
- Key principle being that a CIZ1B protein was identified as associated with Lung Cancer, and critically as it gets absorbed by Fibrinogen, sufficient concentration enables it to be identified at Stage 1 lung cancer rather than latter stages. Typically, lung cancer only identified at stages 3/4, where 5 yr survival is < 10%. Clearly huge benefits in being able to identify and treat quicker.
- Numerous international patents protecting their IP.
- Key piece was then being able to take a laboratory proven test, and make it commercially viable and now have a high throughput Lab developed test which is very close to commercial launch.
- This will initially be in the US, and have a partnership with Corepath laboratories.
- As an already approved oncology testing lab, Corepath cover 22 states and development has a faster track to market launch.
- One very significant development is that they have recently successfully completed an evaluation programme using BioTechne’s high throughput machines giving a big step to commercial launch. BioTechne ($10bn US biotech) also produce monoclonal antibodies, reagents etc… required for the Lab developed test, aswell as having capabilities in lateral flow test production etc…
- Clinical testing is currently underway with Cizzle recently stating they hope to have the test commercially launched in the very near term.
- Away from the US, also have an agreement with ICCAMT in China where significant lung cancer problem (partnership between Bosch, Sinopharm), Allan Syms recently in China (last month). Had concerns whether this wasn’t progressing but AS talked positively about the relationship last month.
- Critically, also looking to develop a lateral flow test which can be used in clinical setting rather than needing to be sent to a lab. Announced c 3 months ago they were accelerating this development and again will benefit from the BioTechne relationship here.
- OBD recently announced a successful prostate cancer test which saw their market cap increase to c £80mn, Ciz currently down at < 10% of that. Additionally, OBD test has a 94% sensitivity when used alongside the traditional PSA test. Cizzle’s test has a 95% sensitivity standalone.
- Away from the lung cancer test, also looking at developments for other cancers using the same application as with CIZ1B to look at use of their developments as companion diagnostics + other
Sign In
Follow the stocks
